Lumida
/ABUS
⌘K
Arbutus Biopharma Corp

Arbutus Biopharma Corp

ABUS
$4.56USD-3.80%-0.18 today

MARKET CAP

900.8M

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$3
$5

AI Summary

Stalk
Buy NowMedium

ABUS remains in Stage 2 Advancing after clearing multi-month resistance with a Momentum Breakout and sustained Lockout Rally, confirming institutional demand. The medium-term bias is bullish, anchored by rising EMAs, but price is extended and overbought, elevating pullback risk. Under a Speculative strategy and the Lockout Rally override, continuation participation is justified now on hold above the breakout zone, with support at the 9/20 EMAs.

  • Phase IIa: 33% of patients achieved undetectable hepatitis B surface antigen
  • $131 M cash funds operations into Q4 2026
  • 2024 net cash burn of $63–67 M pressures $131 M cash balance
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRIC
TREND